Chemomab Therapeutics (NASDAQ:CMMB) Stock Quotes, Forecast and News Summary

Q: What sector and industry does Chemomab Therapeutics (CMMB) operate in?

Chemomab Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Chemomab Therapeutics Stock (NASDAQ: CMMB) stock price, news, charts, stock research, profile.

Open	$1.57
Close	-
Volume / Avg.	77.13K / 242.85K
Day Range	$1.54 - $1.62
52 Wk Range	0.42 - 2.55
Market Cap	$22.18M
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	43
Short Interest	0.42%
Days to Cover	1

Recent News

Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Avi Kapoor

Chemomab Therapeutics Reveals Data From Mid-Stage Study For Liver Disease Candidate, Stock Plunges On Capital Raise

Chemomab Therapeutics reports successful Phase 2 SPRING trial results for CM-101 in primary sclerosing cholangitis, showing safety and efficacy. Key findings include significant improvements in liver stiffness and pruritis, with a favorable safety profile.

Vandana Singh

What's Going On With Fibro-Inflammatory Disease Focused Chemomab Therapeutics On Tuesday?

Chemomab Therapeutics' CM-101 granted new patents in Brazil and Israel, currently in Phase 2 SPRING trial for primary sclerosing cholangitis. Topline data readout expected by mid-2024.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Trends and Forecast

May

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.2

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Open	$1.57
Close	-
Volume / Avg.	77.13K / 242.85K
Day Range	$1.54 - $1.62
52 Wk Range	0.42 - 2.55
Market Cap	$22.18M
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	43
Short Interest	0.42%
Days to Cover	1

About Chemomab Therapeutics Ltd

Sector

Health Care

Industry

Biotechnology

Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and develop...

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Chemomab Therapeutics (CMMB) stock?

You can purchase shares of Chemomab Therapeutics (NASDAQ:CMMB) through any online brokerage.

View our list of the best stock brokerages

Who are Chemomab Therapeutics (CMMB) competitors?

Other companies in Chemomab Therapeutics’s space includes: Vincerx Pharma (NASDAQ:VINC), Aligos Therapeutics (NASDAQ:ALGS), Bolt Biotherapeutics (NASDAQ:BOLT), Geovax Labs (NASDAQ:GOVX) and Palatin Techs (AMEX:PTN).

What is the forecast, or price target, for Chemomab Therapeutics (CMMB) stock?

Chemomab Therapeutics has a consensus price target of $11.75.

What is the current price for Chemomab Therapeutics (CMMB)?

The stock price for Chemomab Therapeutics (NASDAQ: CMMB) is $1.55 last updated September 25, 2024 at 3:14 PM EDT.

Does Chemomab Therapeutics (CMMB) pay a dividend?

There are no upcoming dividends for Chemomab Therapeutics.

When is Chemomab Therapeutics (NASDAQ:CMMB) reporting earnings?

Chemomab Therapeutics’s Q3 earnings are confirmed for Thursday, November 7, 2024.

Is Chemomab Therapeutics (CMMB) going to split?

There is no upcoming split for Chemomab Therapeutics.

What sector and industry does Chemomab Therapeutics (CMMB) operate in?

Chemomab Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Top Stock Ideas Sent Daily — Join and Gain Your Edge